RecruitingNot ApplicableNCT05106608

Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study

Photobiomodulation Therapy With M-health Tool for the Management of Oral Health and Quality of Life in Head and Neck Cancer Patients: LAXER Study


Sponsor

Universidad de Granada

Enrollment

60 participants

Start Date

Jul 13, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The Photobiomodulation therapy could have positive effects on quality of life and oral health in head and neck cancer survivors post-radiotherapy. The improvement in quality of life will be maintained after a follow-up period.


Eligibility

Min Age: 18 Years

Inclusion Criteria9

  • men or women aged 18 years or older and were diagnosed with HNC.
  • chronic xerostomia.
  • received RT in the parotid, submandibular and/or sublingual salivary glands.
  • grade 3 oral dryness according to the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE).
  • medical treatment completed and in complete remission.
  • received medical clearance for participation in this study.
  • at least one month passed since the end of RT to avoid the possible presence of oral mucositis and/or radiodermatitis, which limits adherence to treatment and maximum 36 months.
  • no history of drugs/devices/products (pilocarpine, cevimeline, amifostine, oral devices, humidifiers, or herbs) to prevent or treat xerostomia prior to study inclusion or no change in their use (no change in type or dose) for two months prior to study inclusion.
  • and able to access mobile applications or living with someone who has this ability.

Exclusion Criteria5

  • patients with metastases.
  • a score \<60 on the Karnofsky Performance Status Scale.
  • contraindications to receiving PBM therapy (e.g., cardiac arrhythmias, pacemakers, photosensitivity, drugs with photosensitizing action, and pregnancy).
  • other comorbidities such as diabetes and polypharmacy.
  • and retraction of the declaration of consent.

Interventions

DEVICEEnergy density photobiomodulation (7.5)

A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.

DEVICEEnergy density photobiomodulation (3)

A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total). In addition, a mobile health application (LAXER) will be provided.

DEVICESham placebo

In addition, a mobile health application (LAXER) will be provided.


Locations(1)

Faculty of Health Sciences

Granada, Granada, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05106608


Related Trials